McKinney Porcelain Dental Veneers For Alignment Correction, Treatment Updated

Presley Gerber, son of Cindy Crawford and model, dies at 27

LOS ANGELES — Presley Gerber, the son of supermodel Cindy Crawford and businessperson Rande Gerber, died Sunday at age 27, a family representative said. Gerber died at a rehabilitation facility, according to online records of the Los Angeles County Medical Examiner. The medical examiner did not provide a cause of death Sunday. An autopsy was performed, but more testing is required before investigators can give a cause, according to the medical examiner’s website. The death was confirmed by Allie Jenkins, a representative for Crawford and Rande Gerber, who were married in 1998. “The family is asking for privacy during this very difficult and painful time,” Jenkins said in an email Sunday night. Gerber was a model in his own right Gerber was a model and the older brother of model and actor Kaia Gerber. He had been open about his struggles with mental health and substance abuse, documenting his journey on Instagram. He even started a “Mental Health Mondays” series on the platform to raise awareness and share wellness tips. Across multiple episodes, he related his own experiences

Paramount settles with US states to clear Warner Bros. mega-merger

LOS ANGELES — Paramount has reached a settlement with a group of U.S. states that clears the way for its takeover of Warner Bros. Discovery, officials announced Monday, creating a Hollywood empire spanning television, news and cinema. Paramount, which is run by David Ellison, whose ultra-wealthy family has ties to U.S. President Donald Trump, won a bidding war against Netflix in February for control of a stable of assets that includes Warner Bros. Pictures, CNN and the HBO Max streaming service. The Trump administration approved the deal, one of the largest media mergers in years, in June without demanding a change to its business, before 12 U.S. states sued to block the transaction. Financing for the deal reportedly includes about $24 billion in equity from the sovereign wealth funds of Saudi Arabia, Qatar and Abu Dhabi. David Ellison's father, billionaire Oracle founder Larry Ellison, also provided funding and a guarantee. Opponents in the movie industry said the combined company would slash jobs in a Hollywood already under pressure and reduce the number of films produced every year

US, Denmark, Greenland to sign US security deal for Greenland

COPENHAGEN — The United States, Denmark and Greenland will on Tuesday sign the announced U.S. security deal for Greenland on the sidelines of the UN General Assembly in New York, Denmark's government said. U.S. President Donald Trump said last Friday that the arrangement will give America "permanent control" over security for Greenland, an autonomous Danish territory in the Arctic that he has long coveted. The office of Danish Prime Minister Mette Frederiksen said that she, Trump and Greenland's Prime Minister Jens-Frederik Nielsen would sign the deal at 1430 GMT in the UN building in New York. Frederiksen said Monday that the agreement, which has not been published, "recognises" the sovereignty and territorial integrity of the Kingdom of Denmark, as well as the right of the Greenlandic people to self-determination. "It is a good agreement from a Danish point of view," she told Danish radio DR from New York. "And when it benefits the Nordic countries and security in the Arctic region, it also benefits NATO and Europe." Since returning to the White House in January 2025, Trump has repeate

Trump approval falls to career low of 32% as high costs bite, Reuters/Ipsos poll finds

WASHINGTON — President Donald Trump's approval rating fell to 32 percent — the lowest of his political career — as his fellow Republicans soured on his handling of the cost of living amid the unpopular Iran war, a new Reuters/Ipsos poll found. The four-day poll, which closed on Sunday, showed 73 percent of Republicans approved of Trump's job performance, down from 82 percent in a Reuters/Ipsos poll a week earlier. His overall approval stood at 35 percent that week. Trump returned to the White House in January 2025 on promises to tame inflation and end foreign wars. In a Reuters/Ipsos poll conducted in the hours after he was first sworn in, he enjoyed a 47 percent approval rate. Just 17 percent of respondents in the new poll approved of his handling of the cost of living — the top issue Americans say will determine how they vote in the November 3 midterm elections, when Trump's Republicans are defending narrow congressional majorities. Dissatisfaction among Republicans on the subject has been growing since Trump launched the war on Iran in February that has pushed gasoline and die

CIA Director meets with Zelensky at airport in Ireland

CIA Director John Ratcliffe met with Ukrainian President Volodymyr Zelensky at an airport in Ireland on Monday as the two waited for their planes to be refueled en route to the U.S., a person familiar with the meeting told The Hill. Ratcliffe and Zelensky briefly met at Shannon Airport, the source said, who declined to...

California declares state of emergency ahead of El Niño

California's governor on Monday declared a state of emergency as the US west coast readies for what is expected to be a damaging El Niño.

Trump-charmer Mamdani turns raging president into docile guest at Gracie Mansion

A submissive president appears alongside New York City’s mayor following another hourlong closed-door meeting

Scientists are finally starting to figure out Alzheimer’s

A scan of the brain of a patient affected by Alzheimer's disease. | BSIP/UIG Via Getty Images For decades, research into Alzheimer’s disease has made painfully little progress. More than 7 million Americans are living with the disease, which is the most common cause of dementia. It’s incurable, and treatments have been hampered by groupthink, as well as by systemic fraud from some of the field’s most famous researchers. But there are finally signs that the field is turning a corner, including two new drugs, rolled out in the last few years, that can treat Alzheimer’s directly. “If somebody walks into a clinic right now and is diagnosed with Alzheimer’s disease,” Vox senior correspondent Dylan Scott tells Today, Explained co-host Sean Rameswaram, the drugs “will hopefully have some effect in slowing down their cognitive decline.”  As Scott says, “The drug development pipeline is also starting to look much more robust” — even “revolutionary,” to quote one doctor he spoke with. The two talk about why researchers are more optimistic than they have been in years, whether GLP-1 drugs might help prevent Alzheimer’s, and an experimental surgery pioneered by doctors in China that has produced striking — but if unproven — reports of improvement in people with the disease. Below is an excerpt of their conversation, edited for length and clarity. There’s much more in the full podcast, so listen to Today, Explained wherever you get podcasts, including Apple Podcasts, Pandora, and Spotify. You mentioned two treatments. Tell us what they are, Dylan? We have two drugs right now that have been approved by the FDA: lecanemab and donanemab. And these are drugs that target the amyloid plaque in the brain that scientists have long thought might be associated with the development of Alzheimer’s disease. The amyloid hypothesis [the belief that Alzheimer’s is caused by the buildup of deleterious amyloid proteins in the brain] has been very controversial for a while, in part because there were these years and years where we weren’t seeing any progress despite this being the dominant hypothesis about the disease. But we do have these two drugs that in clinical trials have been shown to both clear out the amyloid plaque in somebody’s brain and they do seem to lead to slower cognitive decline for those patients. And the hope is that this is the ground floor. These are the worst drugs, hopefully, that we’re ever going to have and continued scientific discovery and progress with developing drugs will lead to even better treatments in the future. “The hope is that five, 10 years from now, we’ve got a much more robust suite of treatments that can help somebody who’s been diagnosed with Alzheimer’s.” Tell us more about the scientific discovery. You mentioned that there’s promising research beyond amyloid plaques? It’s not like the amyloid hypothesis has been invalidated, but I think our understanding of the disease has become more complex.  We’re realizing that there’s probably also a role for a different kind of protein called tau. There may also be a role with chronic inflammation, your vascular health, your body’s ability to just pump blood through your body may also be playing a role in the development of Alzheimer’s disease. And so now we’re starting to see treatments that target these other things.  The way I’ve been thinking about it is if we used to be putting all of our bets on amyloid, we’re still putting some bets on amyloid, but we’re also putting bets on these other things. And so now there are treatments in the works targeting, for example, these tau proteins. They’re still in the early stages of clinical trials — really at the stage where they’re just checking the safety of these drugs and making sure that somebody can take them without getting really sick, or God forbid, dying or something like that. But even when they’re doing those safety checks, they do start to collect qualitative data about, well, are we starting to see any effects?  Some of the preliminary results from some of these tau targeting treatments that are in the works have looked pretty promising. And so that’s encouraging, obviously. It’s possible that we’re moving towards a future where not unlike cancer treatment, there’s not just one drug for Alzheimer’s disease, but maybe you take a combination of different things that work on different mechanisms for the disease and the collective cumulative effect is that it stops the progression or even reverses it.  The hope is that five, 10 years from now, we’ve got a much more robust suite of treatments that can help somebody who’s been diagnosed with Alzheimer’s. Five, 10 years from now sounds nice, but is there anything else that’s in the cocktail now that people are discovering could be promising for Alzheimer’s? There are also, yes, drugs that millions of people are taking right now for other reasons that might also be able to help with Alzheimer’s disease. And GLP-1s in particular are the big ones. No way! Yeah, I know. These drugs — it seems like every day you see some new headline about this miraculous thing that they can do. Weight loss, smoking, my poker addiction, and…? And it might prevent dementia down the road.  If you step back and think about it, the theory does make some sense. Like I said before, scientists increasingly think there’s an association between your vascular health and your cognitive health, especially as you age. And what do these GLP-1 drugs do? They help people lose weight.  Losing weight helps to lower your blood pressure, lowers your risk of vascular problems, whether it’s heart disease or pulmonary disease or stroke or something like that. So if more and more people take these, they take them earlier in life, they lose weight, they keep it off, they don’t develop these heart or vascular problems, it does make some sense that that may also reduce their risk of developing Alzheimer’s disease.  It’s still sort of theoretical, but the Alzheimer’s Association is putting $100 million behind some research projects to investigate this possible link. We may learn five, 10 years from now, as millions of people are now on these GLP-1 drugs — maybe we start to see Alzheimer’s less often. And that would be another reason to be optimistic that the future for this disease is looking brighter. How about reversing it? Is that still a pie in the sky? It’s out of reach for now. Certainly some of the scientists that I’ve talked to have said, “In theory, it should be possible. Your brain is really resilient. It’s really good at rebuilding itself if you give it the chance.” It seems like it should be possible to stop the progression of the disease eventually, and maybe ultimately reverse it.  Now, there has been some really intriguing, but also mysterious developments around reversing Alzheimer’s, not from scientists based out of the United States, but from scientists in China. People may or may not have seen that there have been videos of these patients who underwent an experimental surgery and the before and after of these videos is incredible. In the before, you’ve got somebody who clearly has Alzheimer’s disease, doesn’t recognize their loved ones, has trouble with their train of thought. In the after videos, it’s like they’re a completely different person. They recognize their loved ones, they’re talking articulately. And so that has, as you can imagine, generated a lot of excitement, also a fair bit of skepticism. Are these videos real? Do we know? We don’t know for sure if they’re real or not. What’s intriguing about this surgery is that the theory of it, at least to me as a lay person, makes some sense.  The gist of this surgery is the surgeons create a drain in the patient’s brain and the drain is supposed to help the brain get rid of these amyloid and tau proteins that we think are associated with Alzheimer’s disease. On a hypothetical level, it makes some sense. And scientists in the United States and Europe and elsewhere have been intrigued enough about these videos and the findings that have been reported in academic journals to set up their own studies to try to replicate these findings.  Now, it’s a crazy story because this scientist in China who pioneered this idea has actually been arrested by the Chinese government. And as I understand it, he’s currently in detention. For what?! The reporting I saw was these seem to be kind of flimsy charges of insurance fraud. The Chinese government has also tried to ban the surgery, at least outside of clinical trial settings. So that’s obviously complicated the story a little bit. But nevertheless, you do have scientists in the US and outside of China who are like, “Well, we at least want to try this for ourselves and see if it works.” It does feel like it’s something that could get people’s hopes up who have been waiting for this for decades. Exactly. I mean, I think this is like the holy grail. Can we find a way, whether through surgery or through pharmaceuticals, to actually reverse these symptoms and restore the person to who they were before Alzheimer’s took over? Because that’s the thing that I think everybody recognizes but is worth emphasizing, is, as one doctor put it to me, and I’ve never forgotten it, Alzheimer’s is a disease unlike any other because it robs you of your identity.  To be able to restore people’s identity through whatever means, that is the goal that all of these scientists are chasing.

Global stocks rally on lower oil prices, US-China hopes

Nvidia, QIA-backed Iambic Therapeutics files for US IPO as biotech boom rolls on

Texas Governor Abbott halts all state-issued permits for data centers until grid audit is complete

Southern Co unit signs deal with Google to add nuclear capacity